利科哈尔科尼B抑制cGAS-STING信号通路,并预防自身免疫性疾病
Wei Luo1, Zheng Song2, Guang Xu3
1Department of Hepatology, the Fifth Medical Center of PLA General Hospital, Beijing 100039, China; School of Pharmacy, Hubei University of Science and Technology, Xianning 437100, China.
International immunopharmacology
|January 17, 2024
概括
从甘中提取的Licochalcone B抑制了STING信号通路. 这种天然化合物显示出治疗与STING通路过度激活相关的自身免疫疾病的潜力.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 细胞基因激活STING (干扰素基因刺激器) 途径,对免疫至关重要,但在持续激活时与艾卡迪-古提耶氏综合征 (AGS) 等自身免疫性疾病有关.
- 持续的STING通路激活导致严重的自身免疫性疾病,突出显示了针对性抑制剂的需要.
研究的目的:
- 调查甘成分Licochalcone B (LicoB) 作为STING信号通路的潜在抑制剂.
- 评估LicoB在STING介导的自身免疫性疾病中的治疗潜力.
主要方法:
- 评估了LicoB对巨细胞中STING通路激活的影响.
- 分析了LicoB对STING-TBK1-IRF3信号轴的影响.
- 在小鼠模型中评估LicoB在降低I型干扰素水平和全身炎症方面的有效性.
主要成果:
- 在巨细胞中,LicoB有效抑制了STING通路的激活.
- LicoB调节了STING-TBK1-IRF3信号级联.
- 在Trex1-/-小鼠中,LicoB抑制了STING激动剂诱导的干扰素产生,并减少了系统性炎症.
结论:
- 利科哈尔康B是一种强大的STING信号通路的抑制剂.
- 利科B在治疗由异常的STING通路激活驱动的疾病方面显示出有前途的治疗效果.
相关概念视频
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
166
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
166
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
120
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
120
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
139
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
139
01:12Role Of Notch Signalling In Intestinal Stem Cell Renewal
2.1K
Notch signaling was first discovered in Drosophila melanogaster, where it is involved in cell lineage differentiation. Notch signaling regulates the maintenance and differentiation of intestinal stem cells or ISCs by controlling the expression of atonal homolog 1 or Atoh1. Atoh1 directs cells to differentiate into secretory cells.
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
2.1K
01:21Drugs for Treatment of Constipation-Predominant IBS
170
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
170